Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Alejandro Segura‐Tudela"'
Autor:
Rodrigo Lázaro‐Gorines, Patricia Pérez, Ignacio Heras‐Murillo, Irene Adán‐Barrientos, Guillermo Albericio, David Astorgano, Sara Flores, Joanna Luczkowiak, Nuria Labiod, Seandean L. Harwood, Alejandro Segura‐Tudela, Laura Rubio‐Pérez, Yudhi Nugraha, Xiaoran Shang, Yuxing Li, Carlos Alfonso, Kaylin A. Adipietro, Dinendra L. Abeyawardhane, Rocío Navarro, Marta Compte, Wenbo Yu, Alexander D. MacKerell Jr, Laura Sanz, David J. Weber, Francisco J. Blanco, Mariano Esteban, Edwin Pozharski, Raquel Godoy‐Ruiz, Inés G. Muñoz, Rafael Delgado, David Sancho, Juan García‐Arriaza, Luis Álvarez‐Vallina
Publikováno v:
Advanced Science, Vol 10, Iss 34, Pp n/a-n/a (2023)
Abstract Administration of neutralizing antibodies (nAbs) has proved to be effective by providing immediate protection against SARS‐CoV‐2. However, dual strategies combining virus neutralization and immune response stimulation to enhance specific
Externí odkaz:
https://doaj.org/article/83ee823ecfc342e88a1c1efafa321622
Autor:
Laura Rubio-Pérez, Rodrigo Lázaro-Gorines, Seandean L. Harwood, Marta Compte, Rocío Navarro, Antonio Tapia-Galisteo, Jaume Bonet, Belén Blanco, Simon Lykkemark, Ángel Ramírez-Fernández, Mariola Ferreras-Gutiérrez, Carmen Domínguez-Alonso, Laura Díez-Alonso, Alejandro Segura-Tudela, Oana Hangiu, Ainhoa Erce-Llamazares, Francisco J. Blanco, Cruz Santos, José L. Rodríguez-Peralto, Laura Sanz, Luis Álvarez-Vallina
Publikováno v:
OncoImmunology, Vol 12, Iss 1 (2023)
ABSTRACTImmune checkpoint blockade (ICB) with antibodies has shown durable clinical responses in a wide range of cancer types, but the overall response rate is still limited. Other effective therapeutic modalities to increase the ICB response rates a
Externí odkaz:
https://doaj.org/article/87732fe8a8464638935a3dfe1b8c3ab0
Autor:
Ángel Ramírez-Fernández, Óscar Aguilar-Sopeña, Laura Díez-Alonso, Alejandro Segura-Tudela, Carmen Domínguez-Alonso, Pedro Roda-Navarro, Luis Álvarez-Vallina, Belén Blanco
Publikováno v:
OncoImmunology, Vol 11, Iss 1 (2022)
Cancer immunotherapy strategies based on the endogenous secretion of T cell-redirecting bispecific antibodies by engineered T lymphocytes (STAb-T) are emerging as alternative or complementary approaches to those based on chimeric antigen receptors (C
Externí odkaz:
https://doaj.org/article/a738330a8b26462fa166a9c5d196ff70
Autor:
Luis Álvarez-Vallina, Pablo Menéndez, Manel Juan, Pedro Roda-Navarro, María L. Toribio, Laura Sanz, Sonia Guedan, Estela Paz-Artal, Pablo Morales, Maria Neves, Carmen Domínguez-Alonso, Anaïs Jiménez-Reinoso, Laura Rubio-Pérez, Ainhoa Erce-Llamazares, Simon Lykkemark, Marta Compte, Seandean L. Harwood, Sergi Betriu, Berta Marzal, Maria Castellà, Alejandro Segura-Tudela, Laura Díez-Alonso, Antonio Tapia-Galisteo, Samanta Romina Zanetti, Francisco Gutierrez-Agüera, Óscar Aguilar-Sopeña, Patricia Fuentes, Lidia Argemí-Muntadas, Clara Bueno, Ángel Ramírez-Fernández, Belén Blanco
Supplementary Data from Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::181012a204af0f13777e162dffd1b6b5
https://doi.org/10.1158/2326-6066.22544789
https://doi.org/10.1158/2326-6066.22544789
Autor:
Luis Álvarez-Vallina, Pablo Menéndez, Manel Juan, Pedro Roda-Navarro, María L. Toribio, Laura Sanz, Sonia Guedan, Estela Paz-Artal, Pablo Morales, Maria Neves, Carmen Domínguez-Alonso, Anaïs Jiménez-Reinoso, Laura Rubio-Pérez, Ainhoa Erce-Llamazares, Simon Lykkemark, Marta Compte, Seandean L. Harwood, Sergi Betriu, Berta Marzal, Maria Castellà, Alejandro Segura-Tudela, Laura Díez-Alonso, Antonio Tapia-Galisteo, Samanta Romina Zanetti, Francisco Gutierrez-Agüera, Óscar Aguilar-Sopeña, Patricia Fuentes, Lidia Argemí-Muntadas, Clara Bueno, Ángel Ramírez-Fernández, Belén Blanco
Chimeric antigen receptor (CAR)–modified T cells have revolutionized the treatment of CD19-positive hematologic malignancies. Although anti-CD19 CAR-engineered autologous T cells can induce remission in patients with B-cell acute lymphoblastic leuk
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49490124e8ea631de7040033e3b6522b
https://doi.org/10.1158/2326-6066.c.6550748.v1
https://doi.org/10.1158/2326-6066.c.6550748.v1
Autor:
Ana María Camacho, Olalla Sierra Tomillo, Belén Gil-Fournier, Rogelio Simón, Alejandro Segura-Tudela, Juan Francisco Quesada-Espinosa, Maria Isabel Arranz Cano, Arancha Díaz de Bustamante, José Miguel Lezana Rosales, Pablo Morales-Pérez, Noemí Núñez, Rubén Pérez de la Fuente, Soraya Ramiro León, María Teresa Darnaude, Maria Isabel Alvarez-Mora, María José Gómez Rodríguez, Rebeca Villares Alonso, Carmen Palma Milla, Patricia Ramos Gómez, M. Moreno-García, Alexandra Juárez Rufián, Ana Arteche-López, Irene Hidalgo Mayoral, Irene Gómez-Manjón, María Teresa Sánchez Calvín
Publikováno v:
Genes, Vol 12, Iss 560, p 560 (2021)
Genes
Volume 12
Issue 4
Genes
Volume 12
Issue 4
Autism spectrum disorder (ASD) is a prevalent and extremely heterogeneous neurodevelopmental disorder (NDD) with a strong genetic component. In recent years, the clinical relevance of de novo mutations to the aetiology of ASD has been demonstrated. C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92756aa87cedeef077669e06ab0e6b63
https://www.mdpi.com/2073-4425/12/4/560
https://www.mdpi.com/2073-4425/12/4/560
Autor:
Edgar Rodriguez de Frias, Alejandro Segura-Tudela, Elena Ana Lopez, Angel Ramirez-Fernandez, Mario Fernández-Ruiz, Antonio Serrano, Maria Lasa-Lazaro, Laura Naranjo, Paloma Talayero, Oscar Cabrera-Marante, Rocío Laguna-Goya, José María Aguado, Rocío García-García, Alberto Utrero-Rico, Mercedes Catalán, Estela Paz-Artal, Joaquin Martinez-Lopez
Publikováno v:
The Journal of Allergy and Clinical Immunology
Journal of Allergy and Clinical Immunology
Journal of Allergy and Clinical Immunology
Background Coronavirus disease 2019 (COVID-19) has rapidly become a global pandemic. Because the severity of the disease is highly variable, predictive models to stratify patients according to their mortality risk are needed. Objective Our aim was to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad8b67d64db4f64e518d386fa09c54cb
https://pubmed.ncbi.nlm.nih.gov/32710975
https://pubmed.ncbi.nlm.nih.gov/32710975
Autor:
Beatriz Martín-Antonio, Belén Blanco, África González-Murillo, Laura Hidalgo, Jordi Minguillón, Gema Pérez-Chacón, Next Generation CART MAD Consortium, Lucía Fernández, Halin Bareke, Andrés París-Muñoz, Adriana Mañas, Cristina Aguirre-Portolés, Alfonso Navarro-Zapata, Carmen Mestre-Durán, Marta Ibáñez-Navarro, Laura Clares-Villa, Sara Naharro, Antonio Perez-Martinez, Marcos Aldea, María Gaibar, Javier Ruiz-Navarro, Manuel Izquierdo, Juan M. Zapata, África González Murillo, Elena García Sánchez, Jorge García Martínez, Alba Rubio San Simón, Blanca Herrero, Gonzalo García Aguilera, Beatriz Horcajo Morera, Manuel Ramírez Orellana, Belén Blanco-Durango, Anais Jiménez-Reinoso, Rodrigo Lázaro-Gorines, Ivana Zagorac, Antonio Tapia Galisteo, Ángel Ramirez-Fernández, Laura Díez-Alonso, Carmen Dominguez-Alonso, Ainhoa Erce-Llamazares, Oana Hangiu, Laura Rubio Pérez, Marina Gómez Rosel, Alejandro Segura Tudela, Javier Arroyo-Ródena, Luis Álvarez-Vallina, Miguel Ángel Rodríguez Milla, Patricia García Rodríguez, Beatriz Somovilla Crespo, Javier García-Castro, Esperanza Esquinas Tarifa, Juana Serrano-López, Pilar Llamas-Sillero, Beatriz Martin-Antonio
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Adoptive T cellular immunotherapies have emerged as relevant approaches for treating cancer patients who have relapsed or become refractory (R/R) to traditional cancer treatments. Chimeric antigen receptor (CAR) T-cell therapy has improved survival i
Externí odkaz:
https://doaj.org/article/49d95b3c222f4b7389eb0625d73c49df